JAK2 Inhibitors RUXOLITINIB in Patients With High or Intermediate Risk Primary or Secondary Myelofibrosis Eligible for Allogeneic Stem Cell Transplantation: a Prospective Multicentric Phase II Study
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Mar 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- 20 Mar 2017 Planned End Date changed from 1 Oct 2017 to 1 Mar 2019.
- 20 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 16 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Oct 2017.